FindTrial
Sign In

IDP-023

DRUG2 trials

Sponsors

Indapta Therapeutics, INC.

Conditions

Autoimmune DiseasesAutoimmune Diseases of the Nervous SystemBlood CancerDemyelinating Autoimmune Diseases, Central Nervous System (CNS)Demyelinating DiseasesImmune System DiseasesMultiple MyelomaMultiple Sclerosis

Phase 1

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RecruitingNCT06119685
Indapta Therapeutics, INC.Blood Cancer, Multiple Myeloma, NHL +4
Start: 2023-10-25End: 2029-12-31Target: 128Updated: 2025-06-03
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
SuspendedNCT06677710
Indapta Therapeutics, INC.Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, Central Nervous System (CNS) +8
Start: 2026-06-30End: 2028-12-31Target: 34Updated: 2025-04-30